source
- Novo and Orbis strike up to $1.4 billion partnership to develop oral peptide macrocycles for cardiometabolic diseaseNovo Pharmaceuticals has entered a partnership with fellow Danish firm Orbis Medicines that could be worth as much as $1.4 billion. The agreement includes upfront payments, downstream payouts and r…
- Lisata acquires Marea Therapeutics, securing $225M financing to advance two mid-stage drugsLisata Therapeutics completed a stock-for-stock acquisition of biotech startup Marea Therapeutics. The transaction includes a $225 million financing round led by existing backers such as Forbion,…